BOSTON, May 21, 2024 /PRNewswire/ -- Haemonetics Corporation ("Haemonetics") (NYSE: HAE) today announced its intention to offer, subject to market and other conditions, $525,000,000 aggregate principal amount of Convertible Senior Notes due 2029 (the "notes") in a private offering (the "offering") to qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended (the "Securities Act"). Haemonetics also expects to grant the initial purchasers of the notes an option to purch ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K ☑ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended March 30, 2024 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-14041 HAEMONETICS CORPORATION (Exact name of registrant as specified in its charter) Massachusetts 04-2882273 (State or other jurisdiction of incorpor ...

Haemonetics (HAE) continues to expand its business, banking on growth drivers like Plasma, Thromboelastography (TEG), Hemostasis Management and the Vascular Closure business. The stock sports a Zacks Rank #1 (Strong Buy). The rollout of Persona — the company's proprietary technology proven to increase yield from 9% to 12% on average — continues to gain momentum, with more than 25 million collections. Some other top-ranked stocks from the broader medical space are Medpace (MEDP) , ResMed (RMD) and Encompass ...

Its earnings are expected to grow 12% in the next five years. HAE's ROE for the trailing 12 months was 4.6%, better than the industry average of 0.2%. Will the Upside Continue? The Zacks Consensus Estimate for HAE's 2025 earnings is pegged at $1.40, indicating a 6.9% increase from the year-ago reported figure. The consensus estimate for 2025 revenues is pegged at $4.46 billion, indicating a year- over-year improvement of 12.6%. Haemonetics is gaining from the newly-completed limited market release of the ne ...

Shares of Haemonetics (HAE) have been strong performers lately, with the stock up 13.4% over the past month. The stock hit a new 52-week high of $97.35 in the previous session. Haemonetics has gained 12.5% since the start of the year compared to the 3.8% move for the Zacks Medical sector and the 2.9% return for the Zacks Medical - Products industry. What's Driving the Outperformance? The stock has an impressive record of positive earnings surprises, as it hasn't missed our earnings consensus estimate in any ...

For new and old investors, taking full advantage of the stock market and investing with confidence are common goals. Zacks Premium provides lots of different ways to do both.Featuring daily updates of the Zacks Rank and Zacks Industry Rank, full access to the Zacks #1 Rank List, Equity Research reports, and Premium stock screens, the research service can help you become a smarter, more self-assured investor.Zacks Premium also includes the Zacks Style Scores.What are the Zacks Style Scores?The Zacks Style Sc ...

Haemonetics Corporation (HAE) delivered adjusted earnings per share (EPS) of 90 cents for the fourth quarter of fiscal 2024, up 16.9% year over year. The bottom line surpassed the Zacks Consensus Estimate by 2.3%.On a GAAP basis, EPS was 40 cents, down 29.8% from the prior-year quarter’s levels.For the full year, adjusted earnings were $3.96 per share, up 30.7% from the year-ago period’s figure. It beats the Zacks Consensus Estimate by 03%.Total RevenuesRevenues increased 12.8% to $343.3 million in the four ...

Haemonetics Corporation (NYSE:HAE) Q4 2024 Earnings Conference Call May 9, 2024 8:00 AM ET Company Participants Olga Guyette - Senior Director of Investor Relations and Treasury Christopher Simon - President and Chief Executive Officer James D'Arecca - Executive Vice President and Chief Financial Officer Conference Call Participants Anthony Petrone - Mizuno Group Larry Solow - CJS Securities Joanne Wuensch - Citi Andrew Cooper - Raymond James Mike Matson - Needham & Company Michael Petusky - Barrington Rese ...

For the quarter ended March 2024, Haemonetics (HAE) reported revenue of $343.29 million, up 12.8% over the same period last year. EPS came in at $0.90, compared to $0.77 in the year-ago quarter.The reported revenue compares to the Zacks Consensus Estimate of $326.95 million, representing a surprise of +5.00%. The company delivered an EPS surprise of +2.27%, with the consensus EPS estimate being $0.88.While investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- and how ...

Haemonetics (HAE) came out with quarterly earnings of $0.90 per share, beating the Zacks Consensus Estimate of $0.88 per share. This compares to earnings of $0.77 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of 2.27%. A quarter ago, it was expected that this provider blood management systems for health care providers and blood collectors would post earnings of $0.97 per share when it actually produced earnings of $1.04, delive ...